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NEW RESEARCH
Maintenance of Efﬁcacy of Lisdexamfetamine
Dimesylate in Children and Adolescents With
Attention-Deﬁcit/Hyperactivity Disorder:
Randomized-Withdrawal Study Design
David R. Coghill, MD, FRCPsych, MBChB, Tobias Banaschewski, MD, Michel Lecendreux, MD,
Mats Johnson, MD, Alessandro Zuddas, MD, Colleen S. Anderson, MEd,
Richard Civil, MD, Matthew Dauphin, MS, Nicholas Higgins, BS,
Andrew Lyne, MSc, CStat, Maria Gasior, MD, PhD, Liza A. Squires, MD
Objective: In this phase 3 extension study, the long-term maintenance of efﬁcacy of lisdexamfet-
amine dimesylate (LDX) in children and adolescents with attention-deﬁcit/hyperactivity disorder
(ADHD)was evaluated using a randomized-withdrawal study design. Method: European and
US patients (6–17 years; N ¼ 276) with ADHD were entered into a 26-week open-label trial of
LDX treatment. Those who completed the open-label period (n ¼ 157) were randomized 1:1
to their optimized dose of LDX (30, 50, or 70 mg per day) or placebo for a 6-week randomized-
withdrawal period (RWP). The primary efﬁcacy measure was the proportion of patients meeting
treatment failure criteria (50% increase in ADHD Rating Scale IV total score and 2-point
increase in Clinical Global Impressions–Severity of Illness [CGI-S] score, compared with RWP
start point). Safety and tolerability were also evaluated. Results: During the RWP (LDX, n¼ 78;
placebo, n ¼ 79), signiﬁcantly fewer patients receiving LDX met treatment failure criteria (15.8%)
compared with those receiving placebo (67.5%; difference ¼ –51.7%; 95% conﬁdence interval ¼
–65.0, –38.5; p < .001 ). Most treatment failures occurred at or before the week 2 visit after ran-
domization. Treatment-emergent adverse events were reported in 39.7% and 25.3% of patients
receiving LDX and placebo, respectively, during the RWP. Conclusions: These data demon-
strate the maintenance of efﬁcacy of LDX during long-term treatment in children and adolescents
with ADHD. The rapid return of symptoms on LDX withdrawal demonstrates the need for
continuing treatment. The safety proﬁle of LDX was consistent with that of other stimulants.
Clinical trial registration information—Double-Blind, Placebo-Controlled, Randomized With-
drawal, Extension, Safety and Efﬁcacy Study of LDX in Children and Adolescents Aged 6-17;
http://clinicaltrials.gov; NCT00784654. J. Am. Acad. Child Adolesc. Psychiatry, 2014;53(6):
647–657. Key Words: attention-deﬁcit/hyperactivity disorder, randomized controlled trial, cen-
tral nervous system stimulants, lisdexamfetamine dimesylate, maintenance of efﬁcacy
A ttention-deﬁcit/hyperactivity disorder(ADHD) is the most common neuro-behavioral disorder in childhood, with an
estimated worldwide prevalence of approximate-
ly 5%.1,2 Pharmacological treatments for ADHD
include amphetamine- and methylphenidate-
based stimulant drugs, the nonstimulant norepi-
nephrine reuptake inhibitor atomoxetine, and the
a2-adrenergic agonists clonidine and guanfacine.
1,3-6
Lisdexamfetamine dimesylate (LDX) is the ﬁrst
prodrug stimulant7 and is currently indicated
for the treatment of ADHD in the USA, Canada,
Brazil and certain European countries. After oral
administration, LDX is rapidly absorbed from
the gastrointestinal tract and is enzymatically
hydrolyzed, primarily in the blood, resulting
in the gradual release of therapeutically active
d-amphetamine and the naturally occurring
amino acid L-lysine.8 The prodrug properties of
LDX provide a long duration of action and low
intra- and inter-patient variability in systemic ex-
posure to d-amphetamine.7,9
Supplemental material cited in this article is available online.
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The short-term efﬁcacy of LDX has been
established in a series of pivotal randomized,
double-blind, placebo-controlled trials in the
USA; signiﬁcant improvements in ADHD Rating
Scale IV (ADHD-RS-IV) scores were seen in chil-
dren (aged 6–12 years), adolescents (aged 13–17
years) and adults (aged 18–55 years) with
ADHD.10-15 In addition, a laboratory school study
in children and a simulated workplace study in
adults showed that the effects of LDX were
ongoing at 13 and 14 hours (these being the last
time points evaluated), respectively.15,16 The
present investigation (SPD489-326; ClinicalTrials.
gov Identiﬁer NCT00784654) was preceded by
a 7-week, phase 3 European trial (SPD489-325;
ClinicalTrials.gov Identiﬁer: NCT00763971) in
336 children and adolescents with ADHD, which
found that both LDX and the reference treatment
OROS-MPH produced signiﬁcantly greater im-
provements than placebo in symptoms and global
improvement, as assessed using the ADHD-RS-
IV and Clinical Global Impressions–Improve-
ment (CGI-I), respectively.13 Adverse events
associated with LDX treatment were consistent
with the known effects of long-acting stimu-
lant use.
Although ADHD is a chronic condition,
studies investigating the long-term maintenance
of effect of therapeutic agents are limited and
are generally not of randomized and controlled
design.17-19 In long-term, open-label studies
of LDX in children and adults with ADHD,
improvements in core symptoms were main-
tained for up to 12 months, with most treatment-
emergent adverse events (TEAEs) being mild or
moderate in severity.20,21 Only 1 randomized
controlled trial has been reported that monitored
the efﬁcacy of LDX treatment over a period of
more than 7 weeks; this study enrolled adults
with ADHD who had received commercially
available LDX for at least 6 months, and included
a 3-week open-label period (OLP) followed by a
6-week randomized-withdrawal period (RWP).17
The present study (SPD489-326) was designed to
evaluate the long-term maintenance of efﬁcacy
of LDX in children and adolescents with ADHD,
and consisted of 2 phases. The ﬁrst phase as-
sessed the efﬁcacy and safety of LDX treatment
throughout an OLP of at least 26 weeks. The
second phase was a RWP that investigated the
need for continued LDX treatment in order to
maintain efﬁcacy.
METHOD
Study Design and Population
SPD489-326 was originally designed as a 52-week,
open-label extension of study SPD489-325. However,
as agreed with regulatory agencies within the Euro-
pean Union, the protocol was amended to include a
ﬁxed-dose OLP and a double-blind, 2-arm, parallel-
group, placebo-controlled RWP (Figure 1); as part of
the amendment, the planned duration of the study was
reduced from 52 weeks to 33 weeks. The antecedent
study (SPD489-325) enrolled children and adolescents
FIGURE 1 Study design. Note: ET ¼ early termination; R ¼ revised protocol. aPatients enrolled from SPD489-325
before the protocol amendment could have attended maintenance period visits for up to 52 weeks (visits 10–17) before
the revised protocol was approved.
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(aged 6–17 years) in Europe with a primary diagnosis
of ADHD. To ensure a sample size sufﬁcient for
assessment of the primary efﬁcacy measure (treatment
failure), the protocol was also amended to allow pa-
tients (aged 6–17 years) with a primary diagnosis of
ADHD from US sites to be evaluated for direct entry
into SPD489-326.
European patients eligible for SPD489-326 had to
have completed at least 4 weeks of double-blind
treatment, reached visit 4 (week 4) and completed the
1-week post-treatment washout in the antecedent
study, without experiencing any clinically signiﬁcant
adverse events that would preclude exposure to LDX.
All patients had ADHD of at least moderate severity,
deﬁned as an ADHD-RS-IV total score of 28 or higher
at baseline of the antecedent study (European patients)
or at visit 1 (US patients). ADHD was diagnosed ac-
cording to the criteria of DSM-IV-TR. Failure to respond
to OROS-MPH therapy was a key exclusion criterion for
both SPD489-326 (US patients) and the antecedent study,
SPD489-325. US patients who had failed to respond to
more than 1 adequate course of amphetamine therapy
were also excluded from SPD489-326. Individuals whose
current ADHD medication provided effective control of
symptoms with acceptable tolerability were excluded, as
were patients with comorbid psychiatric diagnoses with
signiﬁcant symptoms.
Baseline was deﬁned as the baseline of SPD489-325,
or, for directly enrolled US patients, visit 1 of SPD489-
326. The OLP comprised 4 weeks of dose optimization
followed by at least 20 weeks of dose maintenance, and
then a 2-week ﬁxed-dose period (Figure 1). Individuals
enrolled from SPD489-325 before the protocol amend-
ment could have attended maintenance period visits
for up to 52 weeks (visits 10–17).
During dose optimization, all patients were started
at LDX 30 mg per day on the morning after visit 1; if
necessary, the dose was adjusted at subsequent visits in
weekly 20-mg increment(s) to LDX 50 mg per day and
then 70 mg per day until an acceptable response was
achieved (deﬁned as a 30% or greater reduction in
ADHD-RS-IV total score from baseline and a CGI-I
score of 1 or 2, with tolerable side effects). Patients
then continued treatment with LDX during the dose-
maintenance and ﬁxed-dose periods. Further dose ad-
justments based on effectiveness and tolerability were
permitted during the dose-maintenance period but not
during the ﬁxed-dose period that immediately pre-
ceded the randomized withdrawal. Patients were
withdrawn from the study if, during the ﬁxed-dose
period, they required dose adjustments, experienced
unacceptable side effects, or had an ADHD-RS-IV total
score above 22 or a CGI-S score of 3 or more.
At the start of the RWP, eligible patients were ran-
domized in a 1:1 ratio either to continue receiving their
optimal dose of LDX or to switch to placebo for up to 6
weeks (Figure 1). An automated, interactive response
system (accessible by telephone or the Internet) was
used to generate the random (concealed) allocation
sequence, enroll patients, and assign individuals to study
treatments. During the RWP, LDX and placebo products
were overencapsulated and had an identical appearance;
patients, caregivers, and investigators were blinded to
the treatment allocation. Treatment was administered
orally to patients once daily at approximately 7 AM.
The study was conducted in accordance with Inter-
national Conference on Harmonisation (ICH) Guidelines
for Good Clinical Practice (GCP) and the Declaration of
Helsinki. Written informed consent was provided by
each patient’s parent or legally authorized representa-
tive, and documentation of assent (if applicable) by the
patient was required to conﬁrm that he or she was
aware of the investigational nature of the study and
the required procedures and restrictions in accordance
with the ICH GCP Guideline E6 and applicable regula-
tions. The study protocol and amendments (http://
clinicaltrials.gov/ct2/show/NCT00784654) were ap-
proved by the institutional review board or indepen-
dent ethics committee of each center.
Study Measures
The primary efﬁcacy outcome was the proportion of
patients meeting treatment failure criteria by the end of
the RWP. Treatment failure was deﬁned as a 50% or
greater increase in ADHD-RS-IV total score and a 2-
point or greater increase in CGI-S score at any
double-blind visit relative to the start of the RWP (visit
3R). Visits during the RWP were weekly (Figure 1).
Individuals who met the treatment failure criteria
during the RWP were immediately withdrawn from
the study. Secondary efﬁcacy outcomes included the
maintenance of effect of LDX treatment during the
OLP, as assessed using ADHD-RS-IV and CGI-I scores
relative to baseline.
The ADHD-RS-IV, CGI-S, and CGI-I assessments
were conducted by a physician experienced in the
evaluation of children and adolescents with ADHD,
based on information from the patient and their parent.
Patients who were withdrawn from the study were
asked to attend an early termination visit, which
included the same assessments as scheduled for the last
on-treatment study visit (visit 9R).
Adverse events, weight, height, and vital signs were
recorded at all visits. Electrocardiography (ECG) was
performed at screening and at visits 1 (US patients
only), 7, 3R, and 9R/early termination. TEAEs were
deﬁned as such if they started or worsened during the
period between the day of a patient’s ﬁrst dose of study
treatment and the 3 days after cessation of treatment.
Statistical Analysis
The primary efﬁcacy analysis was performed on
the percentage of patients meeting treatment failure
criteria by the end of the RWP using the Cochran–
Mantel–Haenszel (CMH) test stratiﬁed by country.
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RWP endpoint was the last on-treatment visit after
randomization (visit 3R) with a nonmissing assess-
ment. Patients who withdrew from the study during
the RWP and did not provide efﬁcacy data at the early
termination visit were classed as treatment failures, as
were those without an endpoint value. Treatment
failure rates during the RWP were also assessed using
the CMH test at each double-blind visit. The difference
between groups in time to treatment failure (days) was
assessed using the Wilcoxon test, stratiﬁed by country.
Mean changes from baseline in ADHD-RS-IV scores
during the OLP were assessed using a 1-sample t test.
OLP endpoint was the last on-treatment visit after visit
1 with a nonmissing assessment, up to and including
visit 3R (or up to and including visit 17 for patients
who, before the protocol amendment, continued past
visit 9 but did not enter the ﬁxed-dose period). During
the OLP, the CGI-I was analyzed categorically by
calculating the percentage of individuals showing an
improvement (CGI-I score of 1 [very much improved]
or 2 [much improved]).
The open-label safety population and open-label full
analysis set (FAS) included all patients who received at
least 1 dose of study drug during the study. The ran-
domized safety population and randomized FAS
included all patients whowere randomized and received
at least 1 dose of any study treatment during the RWP.
Efﬁcacy outcomes during the OLP and RWP were
assessed in the open-label FAS and randomized FAS,
respectively. The sample size for this study was sufﬁ-
cient to detect treatment failure rates of 20% and 50% in
the LDX and placebo groups, respectively, at a minimum
90% power and a signiﬁcance level of 0.05 (2-sided).
RESULTS
Patient Disposition and Baseline Characteristics
A total of 276 patients were enrolled in SPD489-
326. Of these, 236 patients were from study
SPD489-325 and were enrolled from 37 sites in
Europe (Germany, n ¼ 95; Sweden, n ¼ 49;
Hungary, n ¼ 28; Italy, n ¼ 20; United Kingdom,
n ¼ 16; France, n ¼ 11; Belgium, n ¼ 9; Poland,
n ¼ 8). The remaining 40 patients were directly
enrolled from 4 US sites. At the start of the RWP,
78 patients were randomized to LDX and 79 to
placebo (Figure S1, available online). The open-
label safety population comprised all 276
enrolled patients, and the randomized safety
population comprised all 157 randomized in-
dividuals. Baseline characteristics were similar
across the open-label safety population and both
groups within the randomized safety population
(Table 1). During the study, a serious breach of
GCP at 1 European site resulted in the data from
14 patients being excluded from the efﬁcacy
analysis. The open-label FAS therefore comprised
262 individuals and the randomized FAS com-
prised 153 patients (LDX, n ¼ 76; placebo n ¼ 77).
The study was conducted from January 27, 2009,
to October 26, 2011.
A total of 110 of 276 patients (39.9%) in the
open-label safety population discontinued LDX
treatment before ﬁnishing the open-label period
(27 during dose optimization, 53 during dose
TABLE 1 Baseline Demographics and Clinical Characteristics of Study Patients
Characteristic
Open-Label Safety
Population (N ¼ 276)
Randomized Safety Population
LDX (n ¼ 78) Placebo (n ¼ 79)
Age, y, mean (SD) 10.9 (2.82) 11.0 (2.63) 11.3 (2.58)
Sex, male, n (%) 212 (76.8) 61 (78.2) 62 (78.5)
Age group, n (%)
6e12 years 191 (69.2) 55 (70.5) 50 (63.3)
13e17 years 85 (30.8) 23 (29.5) 29 (36.7)
Race, white, n (%) 257 (93.1) 74 (94.9) 75 (94.9)
BMI, kg/m2, mean (SD) 19.40 (3.461) 19.44 (3.760) 20.17 (3.645)
Baseline ADHD-RS-IV total score, mean (SD) 40.7 (6.86) 41.9 (6.77) 40.2 (6.96)
Baseline CGI-S rating, mean (SD) 4.9 (0.80) 5.1 (0.81) 5.0 (0.72)
ADHD subtype, n (%)
Predominantly inattentive 46 (16.7) 16 (20.5) 11 (13.9)
Predominantly hyperactive/impulsive 7 (2.5) 1 (1.3) 0
Combined 223 (80.8) 61 (78.2) 68 (86.1)
Time since ADHD diagnosis, y, mean (SD) 2.28 (2.693) 2.87 (2.870) 2.46 (2.803)
Note: Age is that at the start of SPD489-325 or, for directly enrolled patients, at the time of informed consent before entering SPD489-326. Measurements
are from the screening visit of SPD489-325 or, for directly enrolled patients, the last assessment before the first dose of study drug. Percentages are
based on the number of patients with data in each treatment group.ADHD ¼ attention-deficit/hyperactivity disorder; ADHD-RS-IV¼ADHD Rating Scale
IV; BMI¼ body mass index; CGI-S¼ Clinical Global ImpressionseSeverity; LDX¼ lisdexamphetamine dimesylate.
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maintenance, and 30 during the ﬁxed-dose
period) (Figure S1, available online). Causes of
discontinuation during the OLP were TEAEs (n ¼
44), refused further study participation (n ¼ 22),
lack of efﬁcacy (n ¼ 21), lost to follow-up (n ¼ 11),
protocol nonadherence/patient noncompliance
(n ¼ 7), and other reasons (n ¼ 5). The ﬁnal dose
of LDX at OLP endpoint was 30 mg per day in 82
patients (29.7%), 50 mg per day in 98 patients
(35.5%), and 70 mg per day in 96 patients (34.8%).
In the LDX group of the randomized safety
population (n ¼ 78), the dose of LDX at RWP
endpoint was 30 mg per day in 19 patients
(24.4%), 50 mg per day in 27 patients (34.6%), and
70 mg per day in 32 patients (41.0%). In the pla-
cebo group of the randomized safety population
(n ¼ 79), the dose of LDX immediately before
switching to placebo was 30 mg per day in 20
patients (25.3%), 50 mg per day in 36 patients
(45.6%), and 70 mg per day in 23 patients (29.1%).
Efﬁcacy
Primary Outcome: Randomized-Withdrawal Period.
Signiﬁcantly fewer patients receiving LDX met
the treatment failure criteria (12/76; 15.8% [95%
CI ¼ 7.6, 24.0]) at RWP endpoint compared with
those receiving placebo (52/77; 67.5% [95% CI ¼
57.1, 78.0]; Figure 2A). The difference between the
FIGURE 2 Treatment failure rates during the randomized-withdrawal period (randomized full analysis set). Note:
LDX ¼ lisdexamphetamine dimesylate; R ¼ revised protocol; V ¼ visit. (a) Treatment failure rates (95% CI) at each visit
and at endpoint. *p ¼ .005, **p ¼ .001, ***p < .001 based on the Cochran–Mantel–Haenszel test stratified by country
comparing the 2 treatment groups. Endpoint was the last on-treatment visit after visit 3R with a nonmissing assessment.
Patients without an endpoint value were classed as treatment failures. Percentages are calculated as the number of
treatment failures (n) divided by the number of patients with data at that visit (N) in each treatment group. (b) Kaplan–
Meier plot of time to treatment failure. Day 0 ¼ start of the randomized-withdrawal period. The difference between
groups in time to treatment failure was significant (p < .001, Wilcoxon test stratified by country). Symbols represent
censored observations.
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LDX group and placebo group in patients
meeting treatment failure criteria was –51.7%
(95% CI ¼ –65.0, –38.5; p < .001). The proportion
of patients meeting relapse criteria was signiﬁ-
cantly lower in the LDX than in the placebo
groups irrespective of age (6–12 years: LDX 10/53
[18.9%], placebo 34/50 [68.0%], p < .001; 13–17
years: LDX 2/23 [8.7%], placebo 18/27 [66.7%],
p < .001), sex (males: LDX 10/59 [16.9%], placebo
42/60 [70.0%], p < .001); females: LDX 2/17
[11.8%], placebo 10/17 [58.8%], p ¼ 0.007), and
region (Europe: LDX 10/66 [15.2%], placebo 45/
66 [68.2%], p < .001; US: LDX 2/10 [20.0%], pla-
cebo 7/11 [63.6%], p ¼ 0.049).
The majority of placebo-treated patients who
met treatment failure criteria did so at or before
the week 2 visit after randomization. Six of 12
patients in the LDX group and 39 of 52 patients in
the placebo group who met the relapse criteria
did so at visits 4R or 5R (Figure 2). Figure 2B
shows a Kaplan–Meier plot of time to treatment
failure during the RWP. The median time to
treatment failure was not calculable for the LDX
group (because less than half of the patients met
treatment failure criteria during the RWP) and
was 17.0 days (95% CI ¼ 12.0, 22.0) for the pla-
cebo group. The difference between groups in
distribution of the time to treatment failure was
signiﬁcant (p < .001).
In supportive analyses, 2 additional deﬁnitions
of treatment failure were deﬁned separately on
the basis of a 50% increase in ADHD-RS-IV total
score or a 2-point change in CGI-S. When
treatment failure was deﬁned as a 50% increase in
ADHD-RS-IV total score, the proportions of
treatment failures (95% CI) at RWP endpoint
were 28.9% (18.8, 39.1) for LDX and 79.2% (70.2,
88.3) for placebo; the difference between the LDX
and placebo groups was –50.3% (–63.9, –36.6).
Similarly, 17.1% (8.6, 25.6) and 68.8% (58.5, 79.2)
of patients receiving LDX and placebo, respec-
tively, met a treatment failure criterion of at least
a 2-point increase from baseline in CGI-S score at
RWP endpoint; the difference between the LDX
and placebo groups was –51.7% (–65.1, –38.4).
Secondary Outcome: Randomized-Withdrawal
Period (ADHD-RS-IV Total Score). At RWP base-
line (visit 3R), mean (SD) ADHD-RS total scores
in the LDX and placebo groups were 10.2 (5.92)
and 9.5 (6.45), respectively (randomized FAS).
Using the last-observation-carried-forwardmethod,
the mean (SD) change from randomized baseline to
endpoint in the LDX group was 1.9 (6.97, n ¼ 73)
compared with 14.5 (9.95, n ¼ 73) in the placebo
group, with a statistically signiﬁcant (p < .001)
least-squares mean difference (LDX – placebo) of
–12.6 (95% CI ¼ –15.4, –9.8).
Secondary Outcomes: Open-Label Period. At base-
line, the mean (SD) ADHD-RS-IV total score was
40.6 (6.8) (open-label FAS). The mean (SD) change
from baseline in ADHD-RS-IV total score at OLP
endpoint was 26.6 (11.4) (p < .001). Signiﬁcant
changes in mean (SD) ADHD-RS-IV subscale
scores were also seen. At baseline, the mean (SD)
score for the hyperactivity/impulsivity subscale
was 18.8 (5.5) and for the inattention subscale was
TABLE 2 Summary of Treatment-Emergent Adverse Events (TEAEs) During Open-Label Period (Open-Label Safety
Population) and Randomized-Withdrawal Period (Randomized Safety Population)
Patients, n (%)
Open-Label Period
(N ¼ 276)
Randomized-Withdrawal Period
LDX (n ¼ 78) Placebo (n ¼ 79)
Any TEAE 227 (82.2) 31 (39.7) 20 (25.3)
Any serious TEAE 12 (4.3) 0 0
Any TEAE leading to discontinuation of study drug 45 (16.3)a 0 1 (1.3)
TEAEs (10% of patients in any treatment group)
Decreased appetite 76 (27.5) 3 (3.8) 0
Headache 58 (21.0) 6 (7.7) 5 (6.3)
Decreased weight 46 (16.7) 2 (2.6) 1 (1.3)
Nasopharyngitis 43 (15.6) 7 (9.0) 3 (3.8)
Anorexia 41 (14.9) 0 0
Insomnia 39 (14.1) 1 (1.3) 1 (1.3)
Vomiting 32 (11.6) 2 (2.6) 1 (1.3)
Note: TEAEs are listed by decreasing frequency in the open-label safety population. LDX ¼ lisdexamphetamine dimesylate.
aOne patient had a TEAE leading to discontinuation that started in the open-label period but ended during the randomized-withdrawal period. In Figure
S1, available online, this patient has been included as withdrawing because of an adverse event during the randomized-withdrawal period.
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21.8 (3.5); at OLP endpoint, reductions of 12.5 (6.3)
and 14.1 (6.4) points, respectively, were seen in
these subscale scores (open-label FAS). At OLP
endpoint, 205 of 257 patients (79.8%) were cate-
gorized as “improved” (CGI-I score of 1 or 2).
Safety. During the OLP, most patients had at
least 1 TEAE (Table 2). Most TEAEs were mild or
moderate in severity; 25 of 276 (9.1%) patients
reported severe TEAEs. Serious TEAEs occurred
in 12 of 276 (4.3%) patients during the OLP.
Syncope, which was required to be reported as a
serious TEAE, was reported in 2 individuals. The
only other serious TEAE to be reported in more
than 1 individual was aggression (n ¼ 2). During
the RWP, no TEAEs were reported in 10% or
more of patients in either treatment group, all
TEAEs were mild or moderate in severity, and no
serious TEAEs occurred (Table 2). No deaths
occurred during the study.
During the OLP, 45 of 276 patients (16.3%)
experienced a total of 77 TEAEs leading to
discontinuation (including 1 patient who had a
TEAE leading to discontinuation that started in
the OLP but continued into the RWP). The most
common TEAEs leading to discontinuation were
insomnia (8 patients, 2.9%), aggression (5 pa-
tients, 1.8%), and decreased appetite, headache,
and depressed mood (each in 4 participants,
1.4%). Three patients reported serious TEAEs
leading to discontinuation (mild syncope [n ¼ 1],
moderate abdominal pain [n ¼ 1], and severe
explosive behavior [n ¼ 1]); all resolved and were
considered by the investigators to be unrelated to
the study treatment. During the RWP, no patient
in the LDX group had a TEAE that led to
discontinuation. One patient in the placebo group
discontinued treatment because of 2 TEAEs
(restlessness and an increase in ADHD behavior).
LDX treatment was associated with modest
increases in mean pulse rate, heart rate, systolic
blood pressure, and diastolic blood pressure. De-
creases were observed in mean body weight from
baseline to OLP endpoint, and from baseline to
RWP endpoint with LDX (Table 3). From baseline
to OLP endpoint, there was a mean (SD) weight
loss of 2.24 (3.9) kg. During the RWP, patients who
continued to receive LDX maintained a stable
weight, whereas those who were randomized to
placebo increased in weight (Table 3).
DISCUSSION
This study was the ﬁrst to use a randomized-
withdrawal design to evaluate the maintenance TA
BL
E
3
Su
m
m
ar
y
of
C
ha
ng
es
to
V
ita
lS
ig
ns
,
W
ei
gh
t,
an
d
El
ec
tr
oc
ar
di
og
ra
m
Pa
ra
m
et
er
s
O
pe
n-
La
be
lS
af
et
y
Po
pu
la
tio
n
(N
¼
27
6)
Ra
nd
om
iz
ed
Sa
fe
ty
Po
pu
la
tio
n
(N
¼
15
7)
Ba
se
lin
e,
m
ea
n
(S
D
)
M
ea
n
Ch
an
ge
(S
D
):
Ba
se
lin
e
to
O
LP
En
dp
oi
nt
Ba
se
lin
e,
m
ea
n
(S
D
)
M
ea
n
Ch
an
ge
(S
D
):
Ba
se
lin
e
to
V
is
it
3R
M
ea
n
Ch
an
ge
(S
D
):
Ba
se
lin
e
to
RW
P
En
dp
oi
nt
LD
X
(n
¼
78
)
Pl
ac
eb
oa
(n
¼
79
)
LD
X
(n
¼
78
)
Pl
ac
eb
oa
(n
¼
79
)
LD
X
(n
¼
78
)
Pl
ac
eb
oa
(n
¼
79
)
Sy
sto
lic
bl
oo
d
pr
es
su
re
,m
m
H
g
10
7.
8
(9
.9
1)
+1
.6
(1
0.
31
)
10
8.
0
(9
.7
3)
10
8.
4
(9
.0
3)
+1
.7
(1
1.
78
)
+1
.2
(9
.1
0)
+1
.5
(1
1.
79
)
e
0.
6
(9
.6
6)
D
ia
sto
lic
bl
oo
d
pr
es
su
re
,m
m
H
g
67
.1
(9
.3
7)
+2
.3
(1
0.
13
)
67
.1
(9
.7
8)
66
.9
(9
.2
7)
+1
.8
(1
0.
91
)
+2
.2
(8
.6
1)
+1
.4
(1
1.
27
)
e
0.
1
(8
.1
2)
Pu
lse
,b
ea
ts/
m
in
77
.3
(1
0.
78
)
+5
.9
(1
2.
61
)
77
.5
(1
2.
33
)
75
.7
(1
0.
17
)
+6
.3
(1
4.
64
)
+4
.7
(1
1.
33
)
+5
.6
(1
5.
52
)
+4
.2
(1
0.
30
)
W
ei
gh
t,
kg
44
.6
6
(1
6.
01
3)
e
2.
24
(3
.8
66
)
45
.1
2
(1
6.
20
9)
47
.4
2
(1
7.
15
0)
2
.3
0
(4
.1
47
)
3
.1
2
(4
.3
64
)
e
2.
06
(4
.4
34
)
e
1.
35
(3
.8
70
)
H
ea
rt
ra
te
,b
ea
ts/
m
in
75
.9
(1
0.
34
)
+7
.8
(1
2.
48
)
76
.8
(1
1.
10
)
75
.1
(1
0.
51
)
+6
.9
(1
3.
00
)
+6
.2
(1
1.
37
)
+6
.1
(1
2.
59
)
+2
.3
(9
.2
9)
Q
Tc
F
in
te
rv
al
,m
s
37
7.
8
(1
5.
41
)
e
1.
1
(1
4.
84
)
37
8.
9
(1
6.
22
)
37
9.
1
(1
4.
97
)
1
.5
(1
4.
67
)
3
.9
(1
1.
95
)
e
3.
1
(1
5.
31
)
e
2.
5
(1
2.
12
)
N
ot
e:
Ba
se
lin
e
m
ea
su
re
m
en
ts
ar
e
fro
m
ba
se
lin
e
of
th
e
an
te
ce
de
nt
st
ud
y
(S
PD
4
8
9
-3
2
5
)o
r,
fo
rd
ire
ct
ly
en
ro
lle
d
pa
tie
nt
s,
vi
si
t1
of
SP
D
4
8
9
-3
2
6
.T
he
op
en
-la
be
lp
er
io
d
(O
LP
)e
nd
po
in
tw
as
th
e
la
st
on
-tr
ea
tm
en
tv
is
it
af
te
rv
is
it
1
w
ith
a
no
nm
is
si
ng
as
se
ss
m
en
t,
up
to
an
d
in
cl
ud
in
g
vi
si
t3
R
(o
ru
p
to
an
d
in
cl
ud
in
g
vi
si
t1
7
fo
rp
at
ie
nt
s
w
ho
co
nt
in
ue
d
pa
st
vi
si
t9
,
w
ith
ou
te
nt
er
in
g
th
e
fix
ed
-d
os
e
pe
rio
d,
be
fo
re
pr
ot
oc
ol
am
en
dm
en
t).
Th
e
ra
nd
om
iz
ed
-
w
ith
dr
aw
al
pe
rio
d
(R
W
P)
en
dp
oi
nt
w
as
th
e
la
st
on
-tr
ea
tm
en
tv
is
it
af
te
r
vi
si
t3
R
w
ith
a
no
nm
is
si
ng
as
se
ss
m
en
t.
Q
Tc
F
¼
Q
T
in
te
rv
al
co
rre
ct
ed
us
in
g
Fr
id
er
ic
ia
’s
fo
rm
ul
a.
a
Th
e
pl
ac
eb
o
gr
ou
p
of
th
e
ra
nd
om
iz
ed
sa
fe
ty
po
pu
la
tio
n
re
ce
iv
ed
lis
de
xa
m
ph
et
am
in
e
di
m
es
yl
at
e
(LD
X)
du
rin
g
th
e
O
LP
an
d
pl
ac
eb
o
du
rin
g
th
e
RW
P.
JOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
VOLUME 53 NUMBER 6 JUNE 2014 www.jaacap.org 653
MAINTENANCE OF EFFICACY OF LDX IN ADHD
of efﬁcacy of LDX in children and adolescents
with ADHD. In patients aged 6–17 years with
ADHD who had maintained responder status
after at least 26 weeks of open-label LDX treat-
ment, long-term efﬁcacy was demonstrated.
There was a signiﬁcantly lower proportion of
treatment failures in the group who continued
LDX treatment in the double-blind RWP com-
pared to those who stopped LDX and switched to
placebo, irrespective of age, sex, or region. In the
placebo group, the return of ADHD symptoms
was usually rapid, with most placebo-treated
patients who met treatment failure criteria do-
ing so at or before the week 2 visit following
discontinuation of LDX. In addition, during the
OLP, ADHD-RS-IV total and subscale scores
were signiﬁcantly reduced, a high percentage of
patients (79.8%) reported an improvement on the
CGI-I at OLP endpoint, and a low proportion of
patients (21/276, 7.6%) discontinued treatment
because of lack of efﬁcacy compared with the
overall proportion of discontinuations during the
OLP (110/276, 39.9%).
Compared with the primary efﬁcacy outcome,
for which treatment failure was based on there
being above-threshold changes in both the
ADHD-RS-IV and the CGI-S, treatment failure
rates based on a 50% change in ADHD-RS-IV
total score alone were higher, with 28.9% of pa-
tients in the LDX group meeting this criterion.
One explanation for this may be that symptoms
were overstated by individuals (or their parents)
worried that they had been assigned to placebo
and were seeking to return to active treatment,
the so called “negative placebo effect.” However,
the treatment failure rates for the 2-point shift in
CGI-S alone were almost identical to the com-
bined rates, suggesting that the changes in the
CGI-S were the main driver for the primary
combined outcome. The differences between the
treatment groups remained constant, irrespec-
tive of whether the combined or separate out-
comes were used, suggesting that a change in
threshold for treatment failure did not differen-
tially favor 1 treatment arm over the other.
Furthermore, supportive analyses conﬁrmed that
symptomatology as assessed using the ADHD-
RS-IV total score was stable in the LDX group
during the RWP but worsened signiﬁcantly in the
placebo group.
The present observations in children and ad-
olescents are supported by recently reported data
from a randomized-withdrawal study of LDX in
adults with ADHD who had been receiving
commercially available LDX for at least 6 months.
After a further 3 weeks of open-label treatment,
patients were randomized in a double-blind
fashion to continue LDX or to switch to placebo
for 6 weeks. Treatment failure, based on the same
criteria as the present study, occurred in 75.0% of
adult patients receiving placebo compared with
8.9% receiving LDX, with most failures occurring
within 1 to 2 weeks of treatment withdrawal.17
Together, these results suggest that the efﬁcacy of
LDX is maintained after long-term treatment in
patients of all ages with ADHD.
Other examples of the use of a randomized-
withdrawal protocol to demonstrate the mainte-
nance of efﬁcacy of ADHD medications are
limited. In children (aged 6–11 years), rates of
withdrawal due to a return to pre-study symp-
toms during a 12-month RWP, after 3 months of
single-blind amphetamine treatment, were sig-
niﬁcantly greater in the placebo group (71%) than
in the amphetamine (29%) group.18 Similarly,
among children and adolescents (aged 6–17
years) who responded to 6 weeks of open-label
treatment with dexmethylphenidate, signiﬁ-
cantly more patients receiving placebo (61.5%)
than dexmethylphenidate (17.1%) met the relapse
criterion of a CGI-I score of 6 or 7 (much worse or
very much worse) during a 2-week RWP.22 Also,
after 12 weeks of open-label atomoxetine, signif-
icantly fewer patients (aged 6–15 years) receiving
atomoxetine (22.3%) than patients receiving pla-
cebo (37.9%) relapsed during a 9-month RWP,
although the small proportion of individuals who
met the relapse criteria (an increased ADHD-RS-
IV total score to 90% of baseline levels and an
increased CGI-S score of at least 2 points) com-
plicates the interpretation of these data.23 Fur-
thermore, when the atomoxetine-treated patients
in this study were subsequently re-randomized to
an additional 6 months of double-blind treatment
with atomoxetine or placebo, relapse rates were
again low in both groups (atomoxetine, 2.5%;
placebo, 12.2%).24 It was suggested that the
low rates of relapse in this study may have been
due to a reduction in the severity of symptoms
at discontinuation compared with study entry,
perhaps reﬂecting ongoing cognitive and emo-
tional development. However, the high pro-
portions of relapse in the present study despite
similar study design and demographics suggest
otherwise. Two randomized-withdrawal studies
of OROS-MPH in adults with ADHD found that
JOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
654 www.jaacap.org VOLUME 53 NUMBER 6 JUNE 2014
COGHILL et al.
the return of symptoms was numerically but not
signiﬁcantly greater in patients randomized to
placebo compared with continued active treat-
ment.25,26 It is possible that the small sample sizes
and/or prominent placebo effects may have
affected these results, or that the patients may
have developed better coping or adaptive skills
during their extended period of stimulant therapy.
In the present study, LDX was generally well
tolerated, with TEAEs leading to discontinuation
reported by 16.3% of patients during the OLP. The
proﬁle of TEAEs seen with LDX was consistent
with that reported in previous LDX studies in
children and adolescents with ADHD.11-13,15 No
new clinically concerning or unexpected TEAEs
occurred. The TEAEs most commonly reported
during the RWP (decreased appetite, headache,
weight decrease, nasopharyngitis, anorexia,
insomnia, and vomiting) were consistent with the
known effects of stimulant treatment. The lower
incidence of TEAEs in the RWP than the OLP may
have been related to the shorter duration of
treatment or the discontinuation of patients with
TEAEs during the OLP. During the RWP, the
overall incidence of TEAEswas greater in the LDX
group than in the placebo group; this may have
been due to the higher rate of treatment failure and
thus shorter duration of exposure in the placebo
group than in the LDX group. Discontinuation of
LDX treatment during the RWP was not associ-
ated with any safety concerns. Effects on weight
and vital signs were modest and consistent with
those observed with stimulant therapy.
A key strength of the randomized-withdrawal
study design is that it allows the assessment of
longer-term efﬁcacy of a treatment using an ex-
perimental approach but without the ethical
issues raised by asking participants to accept the
possibility of long-term treatment with placebo.
The randomized-withdrawal study design com-
bines a randomized, double-blind, placebo-
controlled methodology with the option of a
rapid return to active treatment in patients who
experience a return of symptoms when switched
to placebo. In contrast, long-term, randomized,
double-blind, placebo-controlled trials require
patients to be assigned to placebo for extended
periods, to their possible detriment; and long-
term, open-label trials, which do have the
advantage of approximating to real-world treat-
ment, lack the experimental rigor of randomized,
double-blind, placebo-controlled studies. The
open label run-in to the randomized withdrawal
also allows the researcher to focus attention
during the experimental phase on known treat-
ment responders, who more closely resemble
those individuals who, in actual clinical practice,
will be most likely to remain on medication over
the long term. Other strengths of SPD489-326
include a patient population of both children
(aged 6–12 years) and adolescents (aged 13–17
years) enrolled from 9 different countries and the
relatively long duration of at least 26 weeks. In
addition, this study used a composite deﬁnition
of treatment failure that required worsening on
2 different clinical assessment scales, 1 scale
measuring symptoms (ADHD-RS-IV) and the
other measuring function (CGI-S). Therefore,
treatment failure in this study reﬂects a pro-
nounced level of symptom return.
A potential limitation of the study is that the
population of patients entering the RWP would
have been enriched for LDX responders, as pa-
tients who did not beneﬁt from, or could not
tolerate, LDX were withdrawn during the OLP.
However, it should be noted that this patient
population reﬂects those individuals who would
be taking LDX long-term in routine clinical
practice. A further potential limitation concerns
the requirement for patients to meet treatment
failure criteria on only 1 occasion. It is possible
that, for some individuals for whom relapse
occurred early (i.e., within the ﬁrst week after
randomization), this represented a “rebound”
due to withdrawal that would have settled over
time. Although this is possible, we believe that a
gap of 1 week between randomization and
assessment was adequate to allow such with-
drawal effects to wear off. Finally, it should be
acknowledged that treatment failure criteria
during the RWP (50% increase in ADHD-RS-IV
total score and a 2-point increase in CGI-S
score) differed from that used to determine an
acceptable response during dose optimization
(30% reduction in ADHD-RS-IV total score and
a CGI-I score of 1 or 2). However, any possible
impact of this difference would be expected to
apply equally to both treatment groups.
In summary, this placebo-controlled, double-
blind, randomized-withdrawal study demon-
strates the maintenance of efﬁcacy of LDX after
long-term treatment in children and adolescents
with ADHD. There are few long-term controlled
studies in children and adolescents with ADHD
that have evaluated maintenance of efﬁcacy
versus placebo, and the results of this study
JOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
VOLUME 53 NUMBER 6 JUNE 2014 www.jaacap.org 655
MAINTENANCE OF EFFICACY OF LDX IN ADHD
therefore represent an important addition to the
evidence base in this ﬁeld. Furthermore, this is
the ﬁrst long-term study of LDX that includes
European patients. The rapid return of symptoms
after LDX withdrawal shows the need for
continuing treatment in children and adolescents
with ADHD and the importance of adherence to
treatment. Further studies are warranted to assess
longer-term effectiveness and safety outcomes. &
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FIGURE S1 Patient disposition during the open-label and randomized-withdrawal periods. Note: FAS ¼ full analysis
set; GCP ¼ Good Clinical Practice; LDX ¼ lisdexamphetamine dimesylate.aSPD489-326 was originally designed as a
12-month open-label study; the protocol was amended to include a fixed-dose period and double-blind randomized-
withdrawal period.
110 terminated open-label period early
• 44 adverse events
• 22 refused further study participation
• 21 lack of efficacy
• 11 lost to follow-up
• 7 protocol non-adherence/ patient non-compliance
• 5 other reasons
7 completed original protocol designa
1 completed open-label period but not randomized
1 had a missing end of study page
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157 underwent randomization
78 randomized to LDX
Randomized safety population
79 randomized to placebo
Randomized safety population
18 terminated randomized-withdrawal 
period early
• 8 met relapse criteria
• 5 lack of efficacy
• 1 refused further study 
participation
• 2 protocol non-adherence/patient 
non-compliance
• 1 adverse event
• 1 other reason
60 completed randomized-
withdrawal period
16 completed randomized-
withdrawal period
63 terminated randomized-withdrawal 
period early
• 35 met relapse criteria
• 18 lack of efficacy
• 7 refused further study 
participation
• 1 protocol non-adherence/patient 
non-compliance
• 1 adverse event
• 1 other reason
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Open-label safety population
276 patients enrolled
(236 patients from antecedent study,
40 patients directly enrolled from US sites)
Open-label full analysis set
262 patients enrolled
(14 patients from one site excluded from 
FAS owing to serious breach of GCP)
Randomized full analysis set
n = 76
(2 patients excluded from FAS 
owing to serious breach of 
GCP)
Randomized full analysis set
n = 77
(2 patients excluded from FAS 
owing to serious breach of 
GCP)
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